In this episode, Why Location Matters: Country and Site Placement Strategy, we explore why geography is more than a backdrop—it is a strategic lever in early phase oncology trials. From patient access and regulatory timelines to invest...

Rare diseases are often misunderstood—and Primary Sclerosing Cholangitis (PSC) is no exception.This Rare Disease Day, join Fortrea and patient advocate leaders to explore why early patient engagement, smarter trial design, and global col...

In this episode, we talk through what sponsors really need to think about when navigating regulatory pathways for cell and gene therapies. We cover everything from early conversations with regulators and managing CMC risk, to using accelerated ...

In this episode, Fortrea experts discuss how external control arms can enable efficient and ethical cell and gene therapy trials, particularly in rare diseases where traditional control arms are challenging. The conversation highlights study de...

In this episode we focus on one of the most dynamic regions in the CGT space: China. Why is this important? China has roughly become a major hub for cell and gene therapy research, driven by regulatory innovation, technological progress, and si...